The following is a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech stocks that hit 52-week highs Sept. 25.)
Coherus Biosciences Inc CHRS
The Medicines Company MDCO
Down In The Dumps
(Biotech stocks that hit 52-week lows Sept. 25.)
Adaptive Biotechnologies Corp ADPT
Advaxis, Inc. ADXS
AnaptysBio Inc ANAB
Aridis Pharmaceuticals Inc ARDS
AzurRx BioPharma Inc AZRX (announced lackadaisical efficacy data for pancreatic insufficiency drug)
BridgeBio Pharma Inc BBIO
Calithera Biosciences Inc CALA
China SXT Pharmaceuticals Inc SXTC
Catalyst Biosciences Inc CBIO
Cellectis SA CLLS
CytomX Therapeutics Inc CTMX
DelMar Pharmaceuticals Inc DMPI
Eloxx Pharmaceuticals Inc ELOX
Exagen Inc XGN (IPOed on Sep. 16)
Five Prime Therapeutics Inc FPRX
Fulcrum Therapeutics Inc FULC
Gemphire Therapeutics Inc GEMP
Kalvista Pharmaceuticals Inc KALV
Kiniksa Pharmaceuticals Ltd KNSA
Myovant Sciences Ltd MYOV
Neon Therapeutics Inc NTGN
Novelion Therapeutics Inc NVLN
Nuvectra Corp NVTR
Onconova Therapeutics Inc ONTX
PDS Biotechnology Corp PDSB
Plus Therapeutics Inc PSTV
Sarepta Therapeutics Inc SRPT
Seelos Therapeutics Inc SEEL
Sophiris Bio Inc SPHS
Spring Bank Pharmaceuticals Inc SBPH
Stealth BioTherapeutics Corp MITO
Surface Oncology Inc SURF
Tocagen Inc TOCA
Titan Pharmaceuticals, Inc. TTNP
Urogen Pharma Ltd URGN
Vaxart Inc VXRT (announced positive topline results for an early-stage study of its oral tableted bivalent norovirus vaccine in healthy adults)
Xenetic Biosciences Inc XBIO
Zosano Pharma Corp ZSAN
Stocks In Focus
Enanta Pharma NASH Drug Aces Midstage Study
Enanta Pharmaceuticals Inc ENTA announced topline results from the Phase 2a ARGON-1 study that evaluated its EDP-305 for the treatment of non-alcoholic steatohepatitis, or NASH, which showed that the study met the primary endpoint, with a statistically significant ALT reduction of 28 U/L in the EDP-305, 2.5mg arm compared to 15 U/L in the placebo arm at week 12.
The company also noted that there was a statistically significant reduction in liver fat content with EDP-3-5 at the 2.5mg dose, as measured by MRI-PDFF.
The majority of treatment-emergent adverse events were mild to moderate, Enanta said. Yet pruritus, a treatment-emergent adverse event, was observed in 51% of the subjects in the 2.5mg arm and discontinuation due to pruritus was 20.8% for the 2.5mg arm compared to 1.8% for the 1mg arm.
The stock was down 21.65% at $55.85 in Thursday's premarket session.
See also: The Week Ahead In Biotech: Spotlight On ESMO Conference
Jazz Presents Positive Data For Excessive Daytime Sleepiness Drug
Jazz Pharmaceuticals PLC JAZZ made oral and poster presentations of Phase 3 data onJZP-258 for the treatment of cataplexy and excessive daytime sleepiness in adults with narcolepsy at the World Sleep 2019 conference in Vancouver, Canada.
"These data support the efficacy and overall safety profile of a lower-sodium oxybate formulation for people living with narcolepsy, a chronic condition that may require lifelong therapy," said Jed Black, SVP of sleep and neuroscience at Jazz.
Takeda's Ulcerative Colitis Drug Found Superior to AbbVie's
TAKEDA PHARMACE/S ADR TAK announced the publication in the New England Journal of Medicine of additional data from the VARSITY study.
The study showed the superiority of the gut-selective biologic vedolizumab over AbbVie Inc ABBV's anti-tumor necrosis factor-alpha biologic adalimumab, in achieving the primary endpoint of clinical remission at week 52 in patients with moderately to severely active ulcerative colitis, Takeda said.
Nektar's Drug Shows Promise In Breast Cancer
Updated Phase 1/2 data for NKTR-214 presented by Nektar Therapeutics NKTR at the 5th CRI-CMT-EATI-AACR International Cancer Immunotherapy Conference in Paris, France showed that NKTR-214 in combination with Bristol-Myers Squibb Co BMY's Opdivo showed promising clinical activity in patients with PD-L1 negative baseline tumors.
"Responses were prolonged and occurred in patients with multiple negative predictive factors for clinical benefit with a checkpoint inhibitor, including prior treatment with taxane therapy and multiple sites of metastases," Nektar said.
These data support potential future development of this doublet in combination with chemotherapy in the population of TNBC patients with the highest unmet medical need, the company said.
Zoegnix Refiles NDA For Seizure Drug
Zogenix, Inc. ZGNX said it has resubmitted the NDA for Fintepla for the treatment of seizures associated with Dravet syndrome
The NDA is based on data from two pivotal Phase 3 trials in Dravet syndrome and an interim analysis from an ongoing open-label extension study that included 232 patients treated for up to 24 months.
In April, the company received a refuse to file letter from the FDA, citing non-submission of certain non-clinical studies as well as incorrect version of a clinical dataset contained in the application.
On The Radar
The FDA is set to rule on Johnson & Johnson JNJ's sBLA for daratumumab in combination with bortezomib, thalidomide and dexamethasone in newly-diagnosed multiple myeloma patients who are candidates for autologous stem cell transplant.
GENMAB A/S/S ADR GMAB has licensed daratumumab to J&J's Janssen unit under a 2012 agreement.
Aytu Bioscience Inc AYTU (after the market close)
Applied Genetic Technologies Corp AGTC (after the market close)
Related Link: Axsome Shares Flirt With Record High: How Much Upside Is Left?
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.